Roxana Dronca
Jacksonville College(US)Mayo Clinic in Florida(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Immune Cell Function and Interaction
Most-Cited Works
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial(2014)1,753 cited
- → Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma(2016)1,053 cited
- → Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001(2019)928 cited
- → Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab(2016)741 cited
- → Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma(2016)667 cited
- → Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma(2017)478 cited
- → Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer(2016)333 cited
- → Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab(2018)305 cited
- → Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy(2018)227 cited